Table 2 Pharmacokinetic variables of dihydroartemisinin (DHA), piperaquine (PQ), artemether, lumefantrine, desbuthyl-lumefantrine and moxifloxacin on treatment Day 3 or Day 4
Treatment | Analyte | Cmax | N | tmax | N | AUCa | N | t1/2 | N |
|---|---|---|---|---|---|---|---|---|---|
(ng/mL) | (h) | (ng·h/mL) | (h) | ||||||
DHA-PQP high-fat/low-caloric breakfast (Group 1) | DHA PQ | 242 (39) 923 (41) | 64 64 | 2 [1–4] 4 [2–12] | 64 64 | 655 (34) 8639 (38) | 64 64 | 1.38 (42) NE | 64 |
DHA-PQP high-fat/high-caloric breakfast (Group 4) | DHA PQ | 224 (40) 1390 (31) | 40 40 | 2 [1–4] 4 [2–7] | 40 40 | 656 (33) 12449 (33) | 40 40 | 1.44 (38) NE | 40 |
DHA-PQP fasted (Group 5) | DHA PQ | 173 (41) 461 (58) | 40 40 | 1 [1–4] 3 [2–6] | 40 40 | 502 (35) 4868 (38) | 39 40 | 1.52 (36) NE | 39 |
Artemether-lumefantrine (group 2) | Artemether DHA Lumefantrine | 34.1 (66) 85.8 (45) 19900 (38) | 55 64 64 | 2 [1–5] 2 [1–5] 6 [4–9] | 55 64 64 | 145 (45) 297 (34) 504173 (42) | 24 45 64 | NE 1.43 (49) NE | 46 |
Desbuthyl- lumefantrine | 104 (52) | 64 | 7 [0–13] | 64 | 7639 (52) | 64 | NE | ||
Moxifloxacin (Group 3) | Moxifloxacin | 2490 (18) | 40 | 2 [1–4] | 40 | 33379 (13) | 12 | 8.15 (11) | 12 |
Moxifloxacin (Group 6) | Moxifloxacin | 2880 (15) | 20 | 2 [1–4] | 20 | 34984 (21) | 8 | 8.03 (10) | 8 |
